SECAUCUS, N.J., July 31, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today announced the availability of the AD-Detect™ Test for Alzheimer's ...

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and ...

Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that helps assess the potential risk of developing Alzheimer’s disease. In adding AD-Detect, a single-blood-draw ...

New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (DGX), a ...

Advances in drug treatments for Alzheimer’s disease have opened doors for diagnostics, and Quest is the latest to walk through. The clinical testing giant has put forward a blood test designed to help ...

GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and ...

Advanced diagnostics in brain health, specifically the AD-Detect Alzheimer's portfolio, saw revenue more than double ...

In just one week, Secaucus-based Quest Diagnostics announced two new product offerings: one for at-home consumer use and another for physicians. The consumer product, Genetic Insights, helps people ...

SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ --Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced ...

LOS ANGELES (Reuters) - Quest Diagnostics Inc's molecular test for identifying patients infected with the H1N1 flu virus has been approved by European regulators and is available for distribution to ...

In 2022, revenues from Quest Diagnostics’ COVID-19 tests weighed in at nearly half the size of the previous year’s haul—and the testmaker is now expecting 2023’s COVID-related earnings to shrink to an ...